EC says separate GMP for cell and gene therapies is necessary

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Good manufacturing practice, European union

The European Commission has rejected PIC/S criticism of a plan to develop GMP for advanced therapies and stressed that separate rules will not mean a lowering of standards.

The PIC/S raised concerns about the plan in a letter published Last week​, arguing separate more flexible good manufacturing practice (GMP) rules that take the variability involved in making cell and gene therapies into account would put patient safety at risk.

The Commission rejected this idea, telling us “During the drafting of the Guidelines of Good Manufacturing Practice for ATMPs, particular attention has been paid to ensuring that the adaptations introduced in the GMP framework for ATMPs are compatible with a high level of quality for ATMPs and a high level of patient's protection​."   

It also contested the PIC/S’ other suggestion that separate rules would hinder efforts to harmonize GMP, arguing instead that there is a lack of regulation of advanced therapy medicinal products (ATMP).   

The suggestion that the EU would be applying standards lower than PIC/s is not consistent with the fact that certain PIC/s members do not even regulate ATMPs as medicinal products, and that -in other PIC/s countries- certain categories of ATMPs are not covered under the medicinal products framework​."


The European Commission also reiterated its view that flexible GMP would facilitate development of cell and gene therapy products.

The development of a specific GMP framework is necessary to facilitate the development of these innovative products for the benefit of patients, including also by increasing opportunities of patients to enrol in clinical trials conducted inside the EU​.”

It added that: “Once the Guidelines on Good Manufacturing Practice specific for ATMPs are adopted, references to ATMPs in Annex 2 will become obsolete and the necessary changes should be made to the Annex with a view to ensuring legal certainty for manufacturers of ATMPs.​   

In turn, the repeal of Annex 13 is linked to the requirement in the new Regulation on clinical trials that the principles and guidelines on good manufacturing practice should be adopted in the form of a delegated act​.”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more